CTRI/2022/08/045068招募中3 期
A Multicentric, Randomized, Open Label, Controlled, Phase III Clinical Trial to evaluate theEfficacy, Safety and Tolerability of Fosfomycin (Trometamol) Powder 3 g versusCiprofloxacin Tablets 750 mg in patients with Chronic Bacterial Prostatitis and Chronic Pelvic Pain Syndrome
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients with history of chronic prostatitis and chronic [elvic pain syndrome
- •2.Current clinical signs and symptoms of chronic prostatitis and chronic pelvic pain syndrome.
- •3.Laboratory evidence of CBP at Screening visit
- •4.Willing to adhere to the prohibitions and restrictions specified in this protocol.
排除标准
- •1.Known hypersensitivity or allergy to antibacterial fluoroquinolones or fosfomycin or to any components of the trial medications.
- •2.Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the screening assessment that could interfere with the objectives of the trial or the safety of the patient.
- •3.Patients with known history of prostatic absces
研究者
相似试验
进行中（未招募）
1 期
A study in preterm neonates with Respiratory Distress Syndrome (RDS) to compare CUROSURF® administration through LISA and conventional administration (LISPAP).Treatment of Respiratory Distress Syndrome (RDS) in spontaneously breathing preterm neonates.EUCTR2016-001974-14-Outside-EU/EEAChiesi Farmaceutici S.p.A.
进行中（未招募）
1 期
An international study at different study sites testing the safety and tolerability of a drug, lucinactant, which is to be inhaled as a means to treat breathing problems in babies born prematurely in the 26 to 28 weeks.Respiratory Distress Syndrome (RDS)MedDRA version: 19.1Level: LLTClassification code 10021735Term: Infant respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 19.1Level: LLTClassification code 10038690Term: Respiratory distress syndrome (neonatal)System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 19.1Level: PTClassification code 10028974Term: Neonatal respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-005624-26-PLWindtree Therapeutics, Inc. (formerly Discovery Laboratories, Inc.)64
已完成
2 期
A study to evaluate the efficacy and safety of Nafamostat Mesilate in treatment of Coronavirus infectioCTRI/2020/06/026220Sun Pharmaceutical Industries Limited41
进行中（未招募）
不适用
Proactive treatment with 0.03% tacrolimus cream in children with moderate/severe dermatitisMedDRA version: 17.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2015-001040-11-Outside-EU/EEAAstellas Pharma China, Inc.120
尚未招募
3 期
Efficacy of Ivermectin for the Treatment and Prophylaxis of COVID-19 diseaseCoronavirus disease 2019PACTR202102535686338agos State Ministry of Health240